ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Characterization and therapeutic potential of two Kayvirus phages against methicillin-resistant S. aureus in a rat myositis model.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeMethicillin-resistant Staphylococcus aureus (MRSA) continues to compromise the efficacy of conventional antibiotics, highlighting the urgent need for alternative antimicrobial strategies. This study aimed to isolate, characterize, and evaluate the therapeutic potential of two strictly lytic bacteriophages, Staphylococcus phages EAS1 and EAS2, against MRSA, including their safety and efficacy in an in vivo myositis model.
methodsEAS1 and EAS2 were isolated from wastewater and characterized using transmission electron microscopy, whole-genome sequencing, and in vitro functional assays. Genomic and comparative analyses were performed to assess genome organization and safety-related features. Therapeutic efficacy and toxicity were evaluated in a rat model of MRSA-induced myositis, with assessment of inflammatory mediators and histopathological tissue damage.
resultsBoth phages exhibited broad and potent lytic activity against S. aureus, including MRSA strains, and demonstrated high physicochemical stability and biocompatibility. Both phages possessed large linear dsDNA genomes (∼138-140 kb) encoding over 240 CDSs without lysogeny, virulence, or antibiotic resistance genes and were classified within the Kayvirus genus based on comparative genomics. In vivo, phage treatment caused no detectable hepatic or renal toxicity. EAS2 treatment led to significant modulation of inflammatory mediators, including TNF-α, IL-10, NF-κB, and COX-2, and resulted in reduced histopathological tissue damage compared with untreated control and vancomycin-treated groups.
conclusionThese findings demonstrate the stability, safety, and therapeutic efficacy of bacteriophages EAS1 and EAS2, particularly EAS2, supporting phage therapy as a promising alternative approach for the treatment of MRSA infections.
Indexed as
Identifiers
42474839What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.